Small Olanzpine as an adjunctive treatment for refractory Obsessive - compulsive disorder

Objective:To explore the therapeutic effects and tolerance of Small Olanzpine as augmentation treatment in the patients with refractory obsessive-compulsive disorder (ROCD). Methods: 31 patients with the ROCD were treated with Olanzpine based upon preceding SSRI antidepressants, Others 28 patients were treated with former medicine. Its beginning dosage was 5mg/d and gradually increased, and top dosage was 20mg/d for 8 weeks. Assessments included the Yale-Brown Obsessive Compulsive Scale (YBOCS), Hamilton Rating Scale for Anxiety (HAMA), Global Assessment Scale (GAS) and Treatment Emergent Symptoms Scale (TESS) before treatment and at the end of the 4m and 8th weeks of the study, respectively. Results: At the end of the 8th weeks of the study, the total scores of the YBOCS (12.0±5.4) , HAMA (13.7±3.2) and GAS (48.2±11.7) had significant difference compared with pretreatment (as follows : 29.8±5.4, 23.50±3.61,26.95±10.61) (P0.01); According to the score-reducing rate of the YBOCS: recovery rate was 16% , effective rate 48% and ineffective rate 36% ; side effects were milder and tolerable. Conclusions: Small dose Olanzpine as synergist of SSRI antidepressants in the treatment of patients with refractory obsessive-compulsive disorder has promising prospect.